江苏中慧元通生物科技有限公司

Ab&B BIO-TECH CO.,LTD.JS has 173 million yuan registered capital,with a total investment of 500 million yuan in the first phase of the project and an additional investment of 2 billion yuan in the second phase. The company is committed to the research, registration and application, industrial production and sales of new vaccines for human. Products aim at international standards, in order to substitute imports and realize exports. At present, the company has obtained the clinical approval of four class I new drugs and one class IX new drug,which are respectively tetravalent influenza virus subunit vaccine for children, tetravalent influenza virus subunit vaccine for adults, recombinant herpes zoster vaccine, nine-valent recombinant human papillomavirus vaccine and 23-valent pneumococcal polysaccharide vaccine. At present, the company has 170 team members, and the core team members are all professionals from the field of biological products production and R&D at home and abroad, with

2020-10-22 23:37:58